Chinese Expert Consensus on Management of Special Adverse Effects 
Associated with Lorlatinib

Chinese Expert Consensus on Management of Special Adverse Effects 
Associated with Lorlatinib

Anaplastic lymphoma kinase (ALK) fusions represent the second most common oncogenic driver mutation in non-small cell lung cancer (NSCLC). As the new class of 3rd generation of ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown robust potency and brain-penetrant clinical activity against a wi...

Full description

Bibliographic Details
Main Authors: Qing ZHOU, Shun LU, Yong LI, Fujun JIA, Guanjun LI, Zhen HONG, You LU, Yun FAN, Jianying ZHOU, Zhe LIU, Juan LI, Yi-Long WU, Chinese Thoracic Oncology Group (CTONG), Chinese Expert Consensus on Management of 
Special Adverse Effects Associated with Lorlatinib Workgroup
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2022-08-01
Series:Chinese Journal of Lung Cancer
Subjects:
anaplastic lymphoma kinase
lung neoplasms
lorlatinib
adverse event
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.39

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.39

Similar Items